Tetanus
Immunosuppressive therapies may reduce the immune response to Diphtheria, Pertussis & Tetanus vaccine.
Do not mix this vaccine with any other vaccine in the same syringe or vial
The most common solicited injection site reactions occurring within 0-14 days following vaccination with this were:
- For Adolescents 11-17 years of age: pain (77.8%), swelling (20.9%), erythema (20.8%).
- For Adults 18-64 years of age: pain (65.7%), swelling (21.0%), erythema (24.7%).
The most common solicited systemic reactions occurring within 0-14 days following vaccination with this were:
- For Adolescents 11-17 years of age: headache (43.7%), body ache or muscle weakness (30.4%), tiredness (15.1%).
- For Adults 18-64 years of age: headache (33.9%), body ache or muscle weakness (21.9%).
If Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the risk for Guillain-Barré syndrome may be increased following a subsequent dose of this vaccine
Progressive or unstable neurologic conditions are reasons to defer this vaccination.
Persons who experienced an Arthus-type hypersensitivity reaction following a prior dose of a tetanus toxoid-containing vaccine should not receive Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed unless at least 10 years have elapsed since the last dose of a tetanus toxoid containing vaccine.
Syncope (fainting) can occur in association with administration of injectable vaccines, including Diphtheria, Pertussis & Tetanus vaccine. Procedures should be in place to prevent falling injury and manage syncopal reactions.